GCVRZ: Summary for Sanofi - Contingent Value Right - Yahoo Finance

UK Markets closed

Sanofi - Contingent Value Right (GCVRZ)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.45+0.05 (+12.50%)
As of 12:06PM EST. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous close0.40
Bid0.41 x 2000
Ask0.43 x 2000
Day's range0.39 - 0.45
52-week range0.08 - 0.45
Avg. volume726,750
Market capN/A
PE ratio (TTM)N/A
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
  • Sanofi gets shot in the arm from dollar strength
    AFP11 months ago

    Sanofi gets shot in the arm from dollar strength

    Sanofis' net profit for 2015 came in at 7.4 billion euros ($8.3 billion), up 7.7 percent from the previous year

  • Reuters - UK Focus11 months ago

    MORNING BID EUROPE-German industry - signs of weakness

    German industrial output plunged unexpectedly in December, data showed on Tuesday, in a sign that Europe's largest economy ended 2015 on a weak footing. At the same time, Jens Weidmann, the head of the Bundesbank, has challenged the positive narrative suggesting that an influx of refugees will be positive for the economy, arguing that it will in fact have a dampening effect for a sustained period. An independence push in Catalonia remains a low-lying but ever-present challenge to the unity of King Felipe VI's state, while the inconclusive outcome of December's elections has thrust him into the role of power broker in a country grappling with rapid social change.

  • Reuters - UK Focus11 months ago

    EU drugs agency sets up Zika task force to speed vaccine work

    Europe's drugs regulator said on Monday it had established an expert task force on Zika to advise companies working on vaccines and medicines against the virus, which is suspected of causing a spike in birth defects in Brazil. With no currently approved vaccines or medicines and none even undergoing clinical studies, the move by the London-based European Medicines Agency (EMA) is designed to ensure Zika development work proceeds as rapidly as possible. "The agency is encouraging medicines developers to contact EMA if they have any promising projects in this area.